A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Eszopiclone 2 mg on Sleep/Wake Function in Older Adults with Primary and Comorbid Insomnia

Ancoli‐Israel, Sonia; Krystal, Andrew D.; McCall, W. Vaughn; Schaefer, Kendyl; Wilson, Amy Blank; Claus, Raymond; Rubens, Robert; Roth, Thomas

doi:10.1093/sleep/33.2.225

Cited by 78 publications

(88 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…15 Costs and cost-savings linked to medication are complicated by the inconsistent duration of medication use in clinical trials, even more so in the real world. A brief review of the literature found duration of clinical trials of sedative hypnotics range from short (2 weeks 16,17 ) to moderate (1-3 months [18][19][20] ) to long (6 months 15 ).…”

Section: S C I E N T I F I C I N V E S T I G a T I O N Smentioning

confidence: 99%

Impact of Brief Cognitive Behavioral Treatment for Insomnia on Health Care Utilization and Costs

McCrae

Bramoweth

Williams

et al. 2014

Journal of Clinical Sleep Medicine

View full text Add to dashboard Cite

Study Objectives: To examine health care utilization (HCU) and costs following brief cognitive behavioral treatment for insomnia (bCBTi). Methods: Reviewed medical records of 84 outpatients [mean age = 54.25 years (19.08); 58% women] treated in a behavioral sleep medicine clinic (2005)(2006)(2007)(2008)(2009)(2010) based in an accredited sleep disorders center. Six indicators of HCU and costs were obtained: estimated total and outpatient costs, estimated primary care visits, CPT costs, number of office visits, and number of medications. All patients completed ≥ 1 session of bCBTi. Those who attended ≥ 3 sessions were considered completers (n = 37), and completers with significant sleep improvements were considered responders (n = 32). Results: For completers and responders, all HCU and cost variables, except number of medications, signifi cantly decreased (ps < 0.05) or trended towards decrease at posttreatment. Completers had average decreases in CPT costs of $200 and estimated total costs of $75. Responders had average decreases in CPT costs of $210. No signifi cant decreases occurred for non-completers. Conclusions: bCBTi can reduce HCU and costs. Response to bCBTi resulted in greater reduction of HCU and costs. While limited by small sample size and non-normal data distribution, the fi ndings highlight the need for greater dissemination of bCBTi for several reasons: a high percentage of completers responded to treatment, as few as 3 sessions can result in signifi cant improvements in insomnia severity, bCBTi can be delivered by novice clinicians, and health care costs can reduce following treatment. Insomnia remains an undertreated disorder, and brief behavioral treatments can help to increase access to care and reduce the burden of insomnia. Keywords: Insomnia, health care utilization, costs, brief cognitive behavioral treatment, physician visits, medication Citation: McCrae CS; Bramoweth AD; Williams J; Roth A; Mosti C. Impact of brief cognitive behavioral treatment for insomnia on health care utilization and costs. J Clin Sleep Med 2014;10(2):127-135.http://dx.doi.org/10.5664/jcsm.3436 S C I E N T I F I C I N V E S T I G A T I O N SC hronic insomnia impacts approximately 8% to 10% of adults in the United States population 1 and carries substantial economic burden. Direct costs (i.e., costs directly related to treatment) have been estimated at $13.9 billion annually in the United States, with total treatment costs estimated at $77 to $92 billion. 2 When indirect costs (i.e., lost productivity, insomniarelated accidents, increased medical problems) are included, annual costs exceed $100 billion. 3 Evidence from outside the U.S. reveals a similar pattern. Specifi cally, a study in Quebec, Canada, found that the combined direct and indirect per-person costs of insomnia syndrome (insomnia complaint ≥ 3 nights/ week with > 1 month duration, dissatisfaction with sleep, and daytime impairment; prescription sleep medication ≥ 3 nights/ week) was approximately $5,010; with $293 attributed to direct costs and $4,717...

show abstract

Section: S C I E N T I F I C I N V E S T I G a T I O N Smentioning

confidence: 99%

Impact of Brief Cognitive Behavioral Treatment for Insomnia on Health Care Utilization and Costs

McCrae

Bramoweth

Williams

et al. 2014

Journal of Clinical Sleep Medicine

View full text Add to dashboard Cite

show abstract

“…One trial attempted to measure the proportion of participants who achieved clinically significant improvement in sleep. 78 It defined clinically significant improvement as the attainment of sleep efficacy equal to or greater than the mean in a group of patients without insomnia. More CBT-I participants achieved clinical improvement than passive controls Sleep onset latency was reported in three trials.…”

Section: Sleep Outcomesmentioning

confidence: 99%

Cognitive Behavioral Therapy in the Treatment of Insomnia

Haynes¹,

Talbert²,

Fox³

et al. 2018

Southern Medical Journal

View full text Add to dashboard Cite

“…39 Participants were randomized to 12 continuous weeks of eszopiclone 2 mg or placebo followed by a 2-week single blind placebo run-out period. Compared to placebo, the authors demonstrated significant improvements in subjective measures of total sleep time, sleep latency and wake after sleep onset in those receiving eszopiclone.…”

Section: Safety and Efficacy Of Eszopiclone In The Elderlymentioning

confidence: 99%

“…No evidence of rebound insomnia was noted following discontinuation of therapy. 39 Of note the three trials detailed are the only studies to date which have examined the use of eszopiclone for the treatment of insomnia in the elderly. All three were industry sponsored.…”

Section: Safety and Efficacy Of Eszopiclone In The Elderlymentioning

confidence: 99%

Eszopiclone in the Management of Insomnia Among Elderly Patients

2011

Clinical Medicine Insights: Geriatrics

View full text Add to dashboard Cite

Abstract:Insomnia is an increasingly common disorder in the elderly and can have a profound, negative impact on both health and quality of life. Effective management can mitigate the adverse effects on morbidity and mortality. When possible, treatment of insomnia in the elderly should focus on conservative, non-pharmaceutical strategies and control of any potential co-morbid medical or psychiatric conditions. When needed, pharmacologic agents can be both safe and effective. Several classes are available for the treatment of insomnia. However, given their efficacy, relative safety and tolerability, non-benzodiazepines such as eszopiclone should be considered the mainstay of therapy. Eszopiclone can be a safe and effective agent for the long-term treatment of insomnia in the elderly.

show abstract

A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Eszopiclone 2 mg on Sleep/Wake Function in Older Adults with Primary and Comorbid Insomnia

Abstract: A Long-Term Safety and Efficacy Study of Eszopiclone in Elderly Subjects With Primary Chronic Insomnia; Registration #NCT00386334; URL - http://www.clinicaltrials.gov/ct2/show/NCT00386334?term=eszopiclone&rank=24

Cited by 78 publications

References 28 publications

Impact of Brief Cognitive Behavioral Treatment for Insomnia on Health Care Utilization and Costs

Impact of Brief Cognitive Behavioral Treatment for Insomnia on Health Care Utilization and Costs

Cognitive Behavioral Therapy in the Treatment of Insomnia

Eszopiclone in the Management of Insomnia Among Elderly Patients

Contact Info

Product

Resources

About